Key facts
- This page summarizes Eric Dobmeier's Form 3 filing for Jade Biosciences, Inc. (JBIO).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 May 2025, 17:39.
Eric Dobmeier - 28 Apr 2025 Form 3 Insider Report for Jade Biosciences, Inc. (JBIO)
- Reporting relationship
- Director
- Issuer ticker
- JBIO
- Reported as of
- 28 Apr 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 01 May 2025, 17:39:40 UTC
- Prior SEC filing
- 22 Jul 2024
- Next SEC filing
- 01 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Balta, as attorney-in-fact for Eric Dobmeier
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Dobmeier filed Form 3 for Jade Biosciences, Inc. (JBIO) on 01 May 2025.
Change
- Previous filing in this sequence was filed on 22 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JBIO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 28 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 93,113
- Exercise price
- $2.32
- Footnotes
- F1
JBIO
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 28 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 176,771
- Exercise price
- $6.03
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option represents a right to purchase 93,113 shares of the Issuer's common stock, one quarter of which will vest on October 23, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Footnote F2
This option represents a right to purchase 176,771 shares of the Issuer's common stock, one quarter of which will vest on January 29, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney